Acanthosis nigricans - Awọn Nigricans Acanthosis
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ó wọ́pọ̀ ní àárín àwọn ènìyàn tí ó ṣànra.
relevance score : -100.0%
ReferencesAcanthosis nigricans jẹ ifihan awọ‑ara ti ipo abẹlẹ. Nigbagbogbo o farahan lori awọn agbegbe awọ bi ọrun, awọn apa, ati ikun, tí ó dà bí àbùlé dudu velvety pẹ̀lú àwọn egbégbé tí kò mọ́. Ipo yìí sábà máa ní ìbáṣepọ̀ pẹ̀lú àtọgbẹ́ àti ìtọ́jú insulini, ṣùgbọ́n ní àwọn iṣẹlẹ̀ tó ṣọ́wọn, ó lè tọ́ka sí àkàn inú ara. Ó tún lè hàn nítorí àwọn ọ̀ràn homonu tàbí láti mu àwọn oogun kan pàtó gẹ́gẹ́ bí steroid (sitẹriọdu) àti àwọn oogun iṣakoso ibi.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) jẹ ipo awọ ara ti o wọpọ ti o sopọ si ọpọlọpọ awọn ọran ilera bii insulin resistance, àtọgbẹ, isanraju, awọn aarun kan, awọn iṣoro homonu, àti àwọn àìtó sí àwọn òògùn. Itọju AN fojúṣọ́ lórí yíyanju àwọn iṣoro ilera tó wà nípò rẹ̀. Ní ìbẹ̀rẹ̀, àwọn dókítà ń ṣàyẹ̀wò fún àwọn ààmì insulin resistance, tó lè ní í ṣe pẹ̀lú isanraju, awọ ara tó gíga, titẹ ẹ̀jẹ̀ gíga, àti àtọgbẹ irú 2. Àwọn dókítà sábà máa ń ṣètò topical retinoids gẹ́gẹ́ bí yíyan ìtọ́jú àkọ́kọ́, èyí tó lè ràn wọ́n lọ́wọ́ láti dín àwọ̀ ara pọ̀. Ṣùgbọ́n, wọ́n lè má yípadà patapata àwọ̀ dúdú. Àwọn aṣàyàn ìtọ́jú míì (salicylic acid, podophyllin, urea, calcipotriol) tún nílò ìlò àtìlẹ́yìn nígbà gbogbo.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Àwọn ìdí
Ó máa ń ṣẹlẹ̀ ní àwọn ènìyàn tó kéré jù ọdún 40 lọ; ó lè jẹ́ àìlera jínì àti ó ní í ṣe pẹ̀lú àwọn àìlera endocrine bí hypothyroidism, acromegaly, arun polycystic, diabetes insulin‑resistant, tàbí arun Cushing.
○ Itọju – Oògùn OTC
#40% urea cream